Lupin’s New Jersey Unit Gets One USFDA Observation; Shares Trade Flat

October 13, 2025October 13, 2025

Shares of Lupin Ltd are trading flat after reaching a day’s high of Rs 1,970.50 on 13th October, following an update on its New Jersey manufacturing facility. In an exchange filing, the company stated that the United States FDA has completed a Pre-Approval Inspection at its Somerset, New Jersey facility, which concluded with one observation.

The US FDA inspected Lupin’s New Jersey facility from 29th September to 10th October, 2025. The company stated that it will address the single observation and respond to the FDA within the specified timeframe.

Lupin also reiterated its commitment to complying with CGMP standards across all its facilities.

Earlier this week, the company announced plans to invest $250 million in a new state-of-the-art pharmaceutical manufacturing facility in Coral Springs, Florida. This facility, to be built over five years, will enhance U.S. production of critical respiratory medicines.

At 1:02 PM, the shares of Lupin were trading 0.54% higher at Rs 1,969.80 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!